Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AstraZeneca plc (AZN) vs EPAM Systems Inc (EPAM) Price & Performance

AstraZeneca plcTrade
EPAM Systems IncTrade

Price performance (Past 24H)

Key statistics

AstraZeneca plc vs EPAM Systems Inc — how do they compare? AstraZeneca plc trades at $158.55 (market cap $248.14B), while EPAM Systems Inc trades at $99.32 (market cap $5.15B). The key difference: AstraZeneca plc is far larger — about 48.2× EPAM Systems Inc's market cap, and AstraZeneca plc pays a 2.01% dividend while EPAM Systems Inc pays none. Which is the better fit depends on your goals.

AZNEPAM
Market Cap
$248.14B$5.15B
Sector
HealthTechnology
52-Week High
$209.48$221.40
52-Week Low
$147.06$76.04
Enterprise Value
$275.41B$4.52B
Dividend Yield
2.01%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AstraZeneca plc

AstraZeneca (AZN) trades at $157.39, down 2.79% amid bearish technical signals and merger speculation. The company demonstrates strong fundamentals with revenue growth to $58.74B in 2025 and a net income margin of 17.02%. Recent earnings have consistently beaten estimates, and analyst consensus is positive with 47.5% buy ratings. However, news of potential merger talks with Bristol Myers Squibb and a related legal investigation have introduced volatility.

The outlook is mixed; solid profitability and growth support long-term value, but near-term price pressure from technical indicators and merger uncertainty presents a cautious entry point. Key risks include deal execution challenges and integration complexities should a merger proceed.

EPAM Systems Inc

EPAM Systems trades at $99.00, up 1.67% today, with a bearish technical signal despite recent earnings beats. The stock shows attractive valuation metrics with a P/E of 13.55 and P/S of 0.97, while profitability remains solid with a net margin of 7.15%. Recent news highlights strong Q2 2026 earnings but a lowered revenue outlook due to slower North American growth and a new OpenAI partnership.

Outlook is mixed: strong fundamentals and analyst consensus ($117.27 target) support upside, but technical weakness and growth headwinds pose risks. Investment opportunity lies in valuation discount and AI initiatives, countered by demand volatility and competitive pressures.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About AstraZeneca plc

A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.

Read more on AZN

About EPAM Systems Inc

EPAM Systems Inc provides software product development and digital platform engineering services to clients located around the world. The company services include Software Product Development, Custom Application Development, Application Testing, Enterprise Application Platforms, Application Maintenance, and Support and Infrastructure Management. The company focuses on innovative and scalable software solutions. The company uses industry standard and custom developed technology, tools, and platforms to deliver results to handle business challenges. The company primarily offers its solutions in the following industries: financial services, travel and consumer, software and hi-tech, life sciences and healthcare. The majority of revenue is generated from North American clients.

Read more on EPAM